Two years ago, researchers at the University of Pennsylvania showed for the first time that it was safe and feasible to infuse cancer patients with millions of their own immune cells that had been edited with the DNA-snipping technology known as CRISPR. To make them more efficient tumor torpedoes, scientists added a single synthetic receptor that locks on to a molecule produced by many types of cancer.
Now, a team led by the Bay Area-based biotech PACT Pharma and researchers at the University of California, Los Angeles, have infused individualized cocktails of CRISPR-edited immune cells into 16 cancer patients with minimal and manageable side effects. Each one received a custom mixture of T cells carrying new receptors tuned to their specific tumors.
And unlike earlier efforts, which relied on viral vectors to endow T cells with cancer-targeting capabilities, in this trial researchers engineered this arsenal of cancer-seeking T cells using only CRISPR and a zap of electricity.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.